123 related articles for article (PubMed ID: 20565793)
1. Immunohistochemical evaluation of inflammatory and proliferative markers in adjacent normal thyroid tissue in patients undergoing total thyroidectomy: results of a preliminary study.
Ardito G; Revelli L; Boninsegna A; Sgambato A; Moschella F; Marzola MC; Giustozzi E; Avenia N; Castelli M; Rubello D
J Exp Clin Cancer Res; 2010 Jun; 29(1):77. PubMed ID: 20565793
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of p53 protein expression in papillary thyroid carcinoma.
Morita N; Ikeda Y; Takami H
World J Surg; 2008 Dec; 32(12):2617-22. PubMed ID: 18836853
[TBL] [Abstract][Full Text] [Related]
3. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma.
Tan A; Etit D; Bayol U; Altinel D; Tan S
Ann Diagn Pathol; 2011 Apr; 15(2):108-16. PubMed ID: 21315633
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
5. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
Tong J; Wang Y; Da JP
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications.
Omar E; Madhavan M; Othman NH
Pathology; 2004 Apr; 36(2):152-9. PubMed ID: 15203751
[TBL] [Abstract][Full Text] [Related]
7. Associations Between Nucleus Size, and Immunohistochemical Galectin-3, Cytokeratine-19 and Hbme-1 Markers in Thyroid Papillary Carcinoma: A Morphometric Analyze.
Toy H; Etli O; Celik ZE; Sezgin Alikanoglu A
Pathol Oncol Res; 2019 Jan; 25(1):401-408. PubMed ID: 29150742
[TBL] [Abstract][Full Text] [Related]
8. Coexistence of atypical adenoma, adenoma with bizarre nuclei and follicular variant of papillary carcinoma of the thyroid.
Pusiol T; Zorzi MG; Morichetti D
Indian J Pathol Microbiol; 2013; 56(4):399-401. PubMed ID: 24441230
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic and diagnostic significance of p53 protein expression in papillary thyroid carcinoma.
Shin MK; Kim JW
Asian Pac J Cancer Prev; 2014; 15(5):2341-4. PubMed ID: 24716981
[TBL] [Abstract][Full Text] [Related]
10. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Buergy D; Weber T; Maurer GD; Mudduluru G; Medved F; Leupold JH; Brauckhoff M; Post S; Dralle H; Allgayer H
Int J Cancer; 2009 Aug; 125(4):894-901. PubMed ID: 19480010
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of pl30cas in papillary thyroid carcinoma.
Dilek FH; Aktepe F; Sahin DA; Topak N; Dilek ON
Int Surg; 2008; 93(3):175-80. PubMed ID: 18828274
[TBL] [Abstract][Full Text] [Related]
12. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
13. Expression of RET in follicular cell-derived tumors of the thyroid gland: prevalence and implication of morphological type.
Inaba M; Umemura S; Satoh H; Abe Y; Kurokawa K; Sakai H; Osamura RY
Pathol Int; 2003 Mar; 53(3):146-53. PubMed ID: 12608895
[TBL] [Abstract][Full Text] [Related]
14. Expression of cytokeratin 19 and protein p63 in fine needle aspiration biopsy of papillary thyroid carcinoma.
Bonzanini M; Amadori PL; Sagramoso C; Dalla Palma P
Acta Cytol; 2008; 52(5):541-8. PubMed ID: 18833815
[TBL] [Abstract][Full Text] [Related]
15. Transformation of p53-positive papillary thyroid carcinoma to anaplastic carcinoma of the liver following postoperative radioactive iodine-131 therapy.
Takeshita Y; Takamura T; Minato H; Misu H; Ando H; Yamashita T; Ikeda H; Nakanuma Y; Kaneko S
Intern Med; 2008; 47(19):1709-12. PubMed ID: 18827421
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of S100C in thyroid lesions.
Torres-Cabala C; Panizo-Santos A; Krutzsch HC; Barazi H; Namba M; Sakaguchi M; Roberts DD; Merino MJ
Int J Surg Pathol; 2004 Apr; 12(2):107-15. PubMed ID: 15173915
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies.
Gustafson KS; LiVolsi VA; Furth EE; Pasha TL; Putt ME; Baloch ZW
Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546
[TBL] [Abstract][Full Text] [Related]
18. Coexistence of malignant struma ovarii and cervical papillary thyroid carcinoma.
Leong A; Roche PJ; Paliouras M; Rochon L; Trifiro M; Tamilia M
J Clin Endocrinol Metab; 2013 Dec; 98(12):4599-605. PubMed ID: 24217901
[TBL] [Abstract][Full Text] [Related]
19. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
20. Expression and cellular localization of p8 protein in thyroid neoplasms.
Ito Y; Yoshida H; Motoo Y; Miyoshi E; Iovanna JL; Tomoda C; Uruno T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Matsuura N; Kuma K; Miyauchi A
Cancer Lett; 2003 Nov; 201(2):237-44. PubMed ID: 14607339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
